Urine-based test IDs prostate cancers

Median overall survival has not been reached in the phase I study of SYNC-T Therapy SV-102, an investigational multi-target immunotherapy platform for solid tumors in patients with metastatic prostate cancer, as of the April 1 data cutoff. 

An international phase III clinical trial that treated patients with high-risk localized and locally advanced prostate cancer with apalutamide—a next-generation neoadjuvant androgen-receptor pathway inhibitor—plus hormone therapy before and after prostate cancer surgery, was further validated by a substudy demonstrating a reduced risk of metastasis or death compared with standard of care.